Advocacy related to U.S. trade, tax, and manufacturing policy, including matters affecting pharmaceutical manufacturing, supply chain resilience, and domestic production of active pharmaceutical ingredients (APIs).
2026 · 3rd Quarter (July 1 - Sep 30)
AMBIOPHARM INC.
Filed by THORN RUN PARTNERS.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- THORN RUN PARTNERS
- Client
- AMBIOPHARM INC.
- Filing UUID
- 94d3f21b-8ce4-4080-ab28-485513c057c4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Advocacy related to U.S. trade, tax, and manufacturing policy, including matters affecting pharmaceutical manufacturing, supply chain resilience, and domestic production of active pharmaceutical ingredients (APIs).
Advocacy related to U.S. trade, tax, and manufacturing policy, including matters affecting pharmaceutical manufacturing, supply chain resilience, and domestic production of active pharmaceutical ingredients (APIs).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.